Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD?

Carbery, Isabel; Selinger, Christian P

Carbery, Isabel; Selinger, Christian P.

Affiliation

Carbery I; Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Selinger CP; Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Aliment Pharmacol Ther ; 53(2): 346-347, 2021 01.

Article in En | MEDLINE | ID: mdl-33368516

Subject(s)

Biological Products; Inflammatory Bowel Diseases; Aged; Biological Therapy; Humans; Inflammatory Bowel Diseases/drug therapy; Thyroxine/adverse effects; Treatment Outcome; Triiodothyronine

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Biological Products / Inflammatory Bowel Diseases Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Aliment Pharmacol Ther Year: 2021 Type: Article Affiliation country: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google